News
XRTX
2.300
+5.50%
0.120
Weekly Report: what happened at XRTX last week (0601-0605)?
Weekly Report · 1d ago
XORTX publishes investor presentation on gout, progressive kidney disease drug pipeline
PUBT · 6d ago
Weekly Report: what happened at XRTX last week (0525-0529)?
Weekly Report · 06/01 10:30
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 05/29 21:05
Weekly Report: what happened at XRTX last week (0518-0522)?
Weekly Report · 05/25 10:34
XORTX Raises US$5 Million in Public Offering to Fund Kidney and Gout Drug Programs
TipRanks · 05/19 11:30
XORTX Therapeutics closes US$5 million follow-on offering at US$1.88/share
PUBT · 05/19 11:03
XORTX ANNOUNCES CLOSING OF US$5 MILLION PUBLIC OFFERING
Reuters · 05/19 11:00
XORTX files Q1 2026 unaudited results showing lower cash and equity
TipRanks · 05/19 10:34
Weekly Report: what happened at XRTX last week (0511-0515)?
Weekly Report · 05/18 10:34
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 05/15 17:06
Xortx Therapeutics 2.66M share Spot Secondary priced at $1.88
TipRanks · 05/14 19:08
XORTX Therapeutics Prices US$5 Million Public Offering to Fund Late-Stage Kidney and Gout Pipeline
TipRanks · 05/14 13:28
XORTX THERAPEUTICS INC - OFFERING EXPECTED TO CLOSE ON OR ABOUT MAY 15, 2026
Reuters · 05/14 11:00
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 05/11 12:06
Weekly Report: what happened at XRTX last week (0504-0508)?
Weekly Report · 05/11 10:30
XORTX Says Preliminary Equity Levels Meet Nasdaq Listing Threshold
TipRanks · 05/08 22:12
Weekly Report: what happened at XRTX last week (0427-0501)?
Weekly Report · 05/04 10:28
Weekly Report: what happened at XRTX last week (0420-0424)?
Weekly Report · 04/27 10:31
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 04/24 12:05
More
Webull provides a variety of real-time XRTX stock news. You can receive the latest news about Xortx Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About XRTX
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.